VeraCept IUD Study

This study is being conducted at the University of Pennsylvania to research a non-hormonal, low-dose, copper-releasing contraceptive that is placed in the uterus and is intended to prevent pregnancy, known as VeraCept. This device is experimental and is being developed as a possible method of long-acting reversible contraception.
 
“Experimental” means that VeraCept has not yet been approved by the Food and Drug Administration (FDA) for sale in the United States. 

The study will investigate the safety and effectiveness of VeraCept in preventing pregnancy. We will also be looking at any effects on menstrual cycle periods and bleeding, and assess any side effects. Study participation involves 14 visits over approximately 5 years, as well as monthly telephone calls and completion of a daily electronic chart to record menstrual bleeding, sexual activity, and any side effects. 

Eligible participants:

  • Healthy women ages 18 – 45

  • Have regular menstrual periods

  • Willing to use the study device as their only method of birth control during the study

  • Seeking to avoid pregnancy for the next 5 years

  • Sexually active with a male partner at least once a month

 
Qualified participants will receive:

  • VeraCept IUD

  • Medical exams

  • $50-$100 per completed study visit (a maximum of $3,600 for completing every part of the study)


If you are interested in participating in this study, complete the online pre-screener here or contact Karrin Rutledge at (215) 662-3282 or karrin.rutledge@uphs.upenn.edu for more information.
 

 

Principal Investigator:
Dr. Courtney Schreiber, MD, MPH

 

Study Coordinator:
Karrin Rutledge
karrin.rutledge@uphs.upenn.edu
215-662-3282

© 2017 by Penn Medicine Women's Health Clinical Research Center

University of Pennsylvania, Philadelphia PA

(215) 662-7727